Evidence map›Paper›PMID 36559304›Full record

ArticlePharmaceutics2022

Preliminary Assessment of Intramuscular Depot of Lipid-Based Decoquinate Formulation for Long-Term Chemoprophylaxis of Malaria.

Yinzhou Fan, Li Qin, Zhenping Huang, Shuanghong Liang, Xiaoyi Huang, Sumei Zeng, Yucheng Liu, Hongxing Wang

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Long-acting intramuscular injections of ELQ-331, an antimalarial agent.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yinzhou FanDivision of Nanomedicine, Bluelight Pharmatech, Co., LTD, Science City, Guangzhou 510530, China.
Li QinCAS Lamvac Biotech Co., Animal Service, Guangzhou 510670, China.
Zhenping HuangCAS Lamvac Biotech Co., Animal Service, Guangzhou 510670, China.
Shuanghong LiangDivision of Nanomedicine, Bluelight Pharmatech, Co., LTD, Science City, Guangzhou 510530, China.
Xiaoyi HuangDivision of Nanomedicine, Bluelight Pharmatech, Co., LTD, Science City, Guangzhou 510530, China.
Sumei ZengDivision of Nanomedicine, Bluelight Pharmatech, Co., LTD, Science City, Guangzhou 510530, China.
Yucheng LiuCAS Lamvac Biotech Co., Animal Service, Guangzhou 510670, China.
Hongxing WangDivision of Nanomedicine, Bluelight Pharmatech, Co., LTD, Science City, Guangzhou 510530, China.ORCID 0000-0002-7583-6190
Chinese Academy of Sciences · CNHuazhong University of Science and Technology · CNSouth China University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sustained-release formulations of decoquinate were evaluated for the long-term prophylaxis of malaria. In the initial experiment, mice were protected from liver-stage

Indexed as

cholesteroldecoquinatePlasmodium infectionsustained release

Identifiers

PMID36559304
PMCPMC9782194
OpenAlexW4311616530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.